NASDAQ: ZYNE Shareholder Notice: Lawsuit Alleges Securities Laws Violations by Zynerba Pharmaceuticals, Inc.
A lawsuit was filed on behalf of investors in Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) shares over alleged securities laws violations.
San Diego, CA -- (SBWire) -- 11/05/2019 --The Shareholders Foundation announced that an investor, who purchased shares of Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), filed a lawsuit over alleged violations of Federal Securities Laws by Zynerba Pharmaceuticals, Inc.
Investors who purchased shares of Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 - 1554.
In April 2018, Zynerba Pharmaceuticals, Inc initiated the Phase 2 BELIEVE 1 (Open Label Study to Assess the Safety and Efficacy of Zygel Administered as a Transdermal Gel to Children and Adolescents with Developmental and Epileptic Encephalopathy) clinical trial ("BELIEVE 1 Trial"), a six-month open label multi-dose clinical trial designed to evaluate the efficacy and safety of Zygel in children and adolescents (ages three to seventeen years) with DEE as classified by the International League Against Epilepsy ("ILAE").
On September 18, 2019, during pre-market hours, Zynerba Pharmaceuticals, Inc announced results from the BELIEVE 1 Trial evaluating topical gel Zygel in children and adolescents with DEE. While Zynerba Pharmaceuticals, Inc asserted that Zygel was well-tolerated in the announcement, it also disclosed that, among patients enrolled in the BELIEVE 1 Trial, the rate of treatment emergent adverse events ("TEAEs") was 96%, the rate of treatment related adverse events ("TRAEs") was 60%, and there were ten patients who reported serious adverse events ("SAEs"), of which, "two SAEs (lower respiratory tract infection and status epilepticus) were determined to be possibly related to treatment."
The plaintiff claims that between March 11, 2019, and September 17, 2019, the defendants made false and/or misleading statements and/or failed to disclose that Zygel was proving unsafe and not well-tolerated in the BELIEVE 1 Trial, that the foregoing created a foreseeable, heightened risk that Zynerba would fail to secure the necessary regulatory approvals for commercializing Zygel for the treatment of DEE in children and adolescents, and that as a result, the Company's public statements were materially false and misleading at all relevant times.
Those who purchased shares of Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
Media Relations Contact
View this press release online at: http://rwire.com/1264130